Browse CATs

Browse CATs  internal medicine   cardiology  cardiac arrest

Diagnosis Economics Prognosis Therapy Basic life support DC cardioversion Drugs

Arrhythmias Amiodarone decreases death. Level of evidence 1a Expiry Date October 2003 Cardiac arrest Lidoflazine has no clear effect on cerebral function. Level of evidence 1b- Expiry Date October 2003 Cardiac arrest Buffer therapy had no clear effect on discharge from hospital. Level of evidence 1b- Expiry Date October 2003 Cardiac arrest high-dose adrenaline had no clear effect on survival Level of evidence 1b- Expiry Date October 2003 Cardiac arrest Nimodipine may increase the chance of having neurological deficits. Level of evidence 1b- Expiry Date October 2003 Cardiac arrest no clear benefit from atropine. Level of evidence 2b- Expiry Date December 2003 Cardiac arrest bretylium tosylate had no clear effect. Level of evidence 2b- Expiry Date October 2003 Cardiac arrest bretylium tosylate increased survival to hospital admission. Level of evidence 3b Expiry Date October 2003 Cardiac arrest calcium chloride increased success of resuscitation. Level of evidence 1b- Expiry Date October 2003 Cardiac arrest amiodarone increased survival to hospital admission but not discharge. Level of evidence 1b Expiry Date October 2003 Cardiac arrest no clear role for magnesium in out-of-hospital cardiac arrest. Level of evidence 1b- Expiry Date November 2003 Cardiac arrest out-of-hospital: high-dose epinephrine did not increase survival at 24 hours Level of evidence 1b Expiry Date November 2003 Cardiac arrest no clear benefit from magnesium for in-patients Level of evidence 1b- Expiry Date November 2003 Cardiac arrest asystole: there was no clear benefit from calcium chloride Level of evidence 1b- Expiry Date October 2003 Cardiac arrest ACLS drugs no not improve survival. Level of evidence 2b Expiry Date October 2003 Cardiac arrest vasopressin increased survival at 24 hours, but was not clearly different at discharge. Level of evidence 1b Expiry Date October 2003